Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Mehmet Oz, MD, President Donald Trump's pick for CMS administrator, sat through three hours of questioning March 14 from the Senate Finance Committee.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback